계명대학교 의학도서관 Repository

Efficacy and Safety of CKD-11101 (Proposed Biosimilar of Darbepoetin-Alfa) Compared with Darbepoetin-Alfa in Patients on Hemodialysis: A Randomized, Double-Blinded, Parallel-Group Phase III Study

Metadata Downloads
Author(s)
Yaerim KimSu-Kil ParkWon Yong ChoKwon Wook JooSug Kyun ShinDae Joong KimYong-Lim KimSung Hyun SonWookyung ChungKwang Young LeeSung Kwang ParkJoong Kyung KimSoo Wan KimDuk-Hee KangJin Kuk KimJin Seok JeonKang Wook LeeChang Hwa LeeDong-Jin OhWon Suk AnJong Soo LeeGun Woo KangJun-young DoJung Pyo LeeKyubok Jin
Keimyung Author(s)
Kim, Yae RimJin, Kyu Bok
Department
Dept. of Internal Medicine (내과학)
Journal Title
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Issued Date
2020
Volume
34
Issue
1
Abstract
Background:
Darbepoetin-alfa is an erythropoiesis-stimulating agent (ESA) with a long elimination half-life that achieves better hemoglobin (Hb) stability than short-acting ESAs.

Objective:
We aimed to evaluate the efficacy and safety of intravenous CKD-11101 (a biosimilar of darbepoetin-alfa) compared with those of darbepoetin-alfa in hemodialysis patients.

Methods:
The study was performed in 24 centers in Korea between June 2015 and June 2017. The study subjects were randomized in a double-blind manner. The follow-up duration was 24 weeks, which consisted of 20 weeks of maintenance and 4 weeks of evaluation period. All patients underwent a stabilization period to achieve a target baseline Hb of 10–12 g/dL before randomization. Following randomization, patients received darbepoetin-alfa or CKD-11101 weekly or biweekly.

Results:
A total of 403 patients were randomized into two groups, and a total of 325 patients (80.6%) completed the investigation. The differences between the two groups in terms of change in the average Hb level from baseline to evaluation were not significant. The average administered dose of ESA was similar between the groups. There was no difference in the proportion of patients who maintained the target Hb during the evaluation period [60.4% vs. 66.2% in the CKD-11101 and darbepoetin-alfa groups, respectively (p = 0.3038)]. In addition, the safety analysis, consisting of adverse events and adverse drug reactions, showed comparable results between the two groups.

Conclusion:
The changes in the level of Hb, dose of erythropoietin, and achievement rate of the target Hb during the study period were comparable between the groups. CKD-11101 has an equivalent efficacy and safety compared with darbepoetin-alfa in patients undergoing hemodialysis.
Keimyung Author(s)(Kor)
김예림
진규복
Publisher
School of Medicine (의과대학)
Citation
Yaerim Kim et al. (2020). Efficacy and Safety of CKD-11101 (Proposed Biosimilar of Darbepoetin-Alfa) Compared with Darbepoetin-Alfa in Patients on Hemodialysis: A Randomized, Double-Blinded, Parallel-Group Phase III Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 34(1), 99–110. doi: 10.1007/s40259-019-00396-9
Type
Article
ISSN
1179-190X
Source
https://link.springer.com/article/10.1007%2Fs40259-019-00396-9
DOI
10.1007/s40259-019-00396-9
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/42963
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.